Study has found Noscapine effective in prophylactic treatment for prostate cancer

New collaborative research has revealed a major breakthrough in the use of cough medicine ingredient noscapine as a prophylactic treatment for prostate cancer.

The study findings show that noscapine inhibited tumor growth in mice and also limited the spread of tumors without causing any side effects. Researchers concluded that noscapine administered as a preventive measure may offer significant benefits in the management of prostate cancer.

The study also found that lung metastasis rates were 80% less in the mice pre-treated with noscapine, while the experts noted that the noscapine group suffered no cancer-related weight loss - compared with significant weight loss in the non-noscapine group.

The latest research is the result of ongoing collaborative work between the Prostate Cancer Research and Educational Foundation (PC-REF) and Baltimore-based MedInsight Research Institute. Their previous work has shown that noscapine has properties that limit the growth of prostate cancer.